Article
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Hepatology (Baltimore, Md.) - 1 Apr 2018
Poordad Fred, Pol Stanislas, Asatryan Armen, Buti Maria, Shaw David, Hézode Christophe, Felizarta Franco, Reindollar Robert W, Gordon Stuart C, Pianko Stephen, Fried Michael W, Bernstein David E, Gallant Joel, Lin Chih-Wei, Lei Yang, Ng Teresa I, Krishnan Preethi, Kopecky-Bromberg Sarah, Kort Jens, Mensa Federico J
Abstract excerpt
Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options. MAGELLAN-1 Part 2 was a randomized, open-label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) in patients with chronic HCV and past VF on at least one NS3/4A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.